AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 53 min read$LNTH

Earnings To Watch: Lantheus (LNTH) Reports Q2 Results Tomorrow

Lantheus Holdings (NASDAQ: LNTH) is set to report Q2 results Thursday before the bell. The article notes it beat prior-quarter revenue expectations with $377.3 million revenue, up 1.2% YoY, but missed full-year revenue guidance expectations. For the upcoming quarter, analysts expect revenue down 4.7% YoY. LNTH shares are down 1.8% over a month; average analyst price target is $107.22 vs $100.97.

Original reporting
financialcontent.com
Published Aug 5, 2026, 4:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Earnings To Watch: Lantheus (LNTH) Reports Q2 Results Tomorrow — source image
Source · financialcontent.com
Decision brief

The 30-second read

$LNTHNeutralMed
01

Why it matters

Traders can position for earnings volatility using the stated consensus (revenue -4.7% YoY) and the company’s recent pattern of missing revenue estimates, while monitoring for any guidance changes not provided in the article.

02

Market read

Provides consensus direction and peer read-across context ahead of Lantheus’s scheduled earnings release.

03

What to watch

The article does not mention margins, product mix, or specific radiopharmaceutical demand drivers, which could dominate the earnings reaction versus the headline revenue YoY trend.

Relevance 5/10Novelty 4/10Timing: pre-market Thursday before the bell (earnings release)

Background

The piece is a pre-earnings setup for Lantheus’s Q2 report, referencing last quarter’s beat and the current consensus revenue decline expectation.

Company-level read

Ticker impact

$LNTHNeutralMedium confidence
Context

Lantheus (LNTH) is scheduled to report Q2 results before the bell Thursday, with consensus expecting revenue down 4.7% YoY.

Expected impact

Likely volatility around the open, with upside skew if revenue decline is smaller than the 4.7% YoY expectation or if guidance improves versus prior misses.

Evidence & confidence

The text provides specific consensus direction (revenue -4.7% YoY) and notes prior revenue misses, but it does not disclose any new guidance, filings, or fresh company-specific catalyst beyond the upcoming report.

Market effects

Sector

Peers’ reported Q2 results (GE HealthCare, Baxter) are used as a read-across for healthcare equipment and supplies sentiment into Lantheus earnings.

Regional

No specific regional impact described.

Global

No explicit global demand or regulatory driver mentioned.

Counterpoint

What could challenge this read

If peers’ beats were driven by temporary factors, Lantheus could diverge despite the read-across framing.

Key entities

  • company
    Lantheus Holdings

    Radiopharmaceutical company scheduled to report Q2 results Thursday before the bell.

  • company
    GE HealthCare

    Peer cited as having delivered Q2 revenue growth and a post-results stock jump.

  • company
    Baxter

    Peer cited as having topped Q2 revenue expectations and risen after results.

Read at source← All news

Related articles

AUG 6
$LNTHMed

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Holdings (NASDAQ: LNTH) reported Q2 CY2026 revenue of $388.2 million, up 2.7% year on year, ahead of Wall Street expectations. Non-GAAP adjusted EPS was $1.55, 18.9% above consensus. The article also cites adjusted operating margin of 31% and analyst expectations for revenue to decline 3.2% and full-year EPS to fall from $5.95 to $5.55.

financialcontent.com5 min
AUG 6
$LNTHHighAI 10/10

Lantheus Holdings, Inc. (LNTH): Results of Operations and Financial Condition

Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lnth-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lantheus Reports Second Quarter 2026 Financial Results • Worldwide revenue of $388.2 million in the second quarter of 2026 • GAAP fully diluted earnings per share of $1.11, compared to $1.12 in the second quarter of 2025 • Ad

SEC EDGAR 8-K6 min
AUG 4
$LNTHHighAI 9/10

Curium to buy Lantheus in all

Curium US will buy all outstanding shares of Nasdaq-listed Lantheus for $102.50 per share at closing, plus non-transferable CVRs worth up to $12.00 more if 2030 milestones are met, for up to $114.50 total. The offer is a 38% premium to Lantheus’ 60-day VWAP. Board approved unanimously; deal expected to close in H1 2027.

pharmaceutical-business-review.com6 min
AUG 3
$LNTHMed

TD Cowen downgrades Lantheus stock to hold on Curium deal view

TD Cowen downgraded Lantheus Holdings (LNTH) to Hold from Buy and cut its price target to $102.50 from $110.00. Analyst Tara Bancroft said the Curium deal is fair and sees >50% odds of most contingent value milestones, but less optimism on the top PSMA PET tier. The stock trades near $102.03. Separately, the FDA issued a Complete Response Letter for LNTH-2501.

investing.com4 min
AUG 3
$LNTHHighAI 9/10

Lantheus Holdings To Be Acquired By Curium For Up To $8 Bln

Lantheus (LNTH) said it agreed to be acquired by Curium, backed by CapVest, for up to $8 billion. Curium US will buy all LNTH shares for $102.50 cash plus non-transferable Contingent Value Rights up to $12 per share tied to milestones through 2030. Total up to $114.50 per share, a 38% premium. Deal expected to close in 1H 2027.

rttnews.com4 min